Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
Strahlenther Onkol ; 195(11): 982-990, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31346674

ABSTRACT

PURPOSE: In this pilot trial, we investigate the safety of CT-guided high-dose-rate brachytherapy (HDR-BT) as a local ablative treatment for renal masses not eligible for resection or nephrectomy. METHODS: We investigated renal function after irradiation by HDR-BT in 16 patients (11 male, 5 female, mean age 76 years) with 20 renal lesions (renal cell carcinoma n = 18; renal metastases n = 2). Two patients had previous contralateral nephrectomy and two had ipsilateral partial nephrectomy. Six lesions had a hilar localization with proximity to the renal pelvis and would have not been favorable for thermal ablation. Renal function loss was determined within 1 year after HDR-BT by renal scintigraphy and laboratory parameters. Further investigations included CT and MRI every 3 months to observe procedural safety and local tumor control. Renal function tests were analyzed by Wilcoxon's signed rank test with Bonferroni-Holm correction of p-values. Survival and local tumor control underwent a Kaplan-Meier estimation. RESULTS: Median follow-up was 22.5 months. One patient required permanent hemodialysis 32 months after repeated HDR-BT and contralateral radiofrequency ablation of multifocal renal cell carcinoma. No other patient developed a significant worsening in global renal function and no gastrointestinal or urogenital side effects were observed. Only one patient died of renal tumor progression. Local control rate was 95% including repeated HDR-BT of two recurrences. CONCLUSION: HDR-BT is a feasible and safe technique for the local ablation of renal masses. A phase II study is recruiting to evaluate the efficacy of this novel local ablative treatment in a larger study population.


Subject(s)
Brachytherapy/methods , Carcinoma, Renal Cell/radiotherapy , Kidney Neoplasms/radiotherapy , Radiofrequency Ablation/methods , Radiotherapy Dosage , Radiotherapy, Image-Guided/methods , Tomography, X-Ray Computed , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Kidney/radiation effects , Kidney Function Tests , Kidney Neoplasms/secondary , Male , Patient Safety , Pilot Projects , Radiation Injuries/etiology
2.
Strahlenther Onkol ; 193(8): 612-619, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28341865

ABSTRACT

PURPOSE: To assess the efficacy, safety, and outcome of image-guided high-dose-rate (HDR) brachytherapy in patients with adrenal gland metastases (AGM). MATERIALS AND METHODS: From January 2007 to April 2014, 37 patients (7 female, 30 male; mean age 66.8 years, range 41.5-82.5 years) with AGM from different primary tumors were treated with CT-guided HDR interstitial brachytherapy (iBT). Primary endpoint was local tumor control (LTC). Secondary endpoints were time to untreatable progression (TTUP), time to progression (TTP), overall survival (OS), and safety. In a secondary analysis, risk factors with an influence on survival were identified. RESULTS: The median biological equivalent dose (BED) was 37.4 Gy. Mean LTC after 12 months was 88%; after 24 months this was 74%. According to CTCAE criteria, one grade 3 adverse event occurred. Median OS after first diagnosis of AGM was 18.3 months. Median OS, TTUP, and TTP after iBT treatment were 11.4, 6.6, and 3.5 months, respectively. Uni- and multivariate Cox regression analyses revealed significant influences of synchronous disease, tumor diameter, and the total number of lesions on OS or TTUP or both. CONCLUSION: Image-guided HDR-iBT is safe and effective. Treatment- and primary tumor-independent features influenced survival of patients with AGM after HDR-iBR treatment.


Subject(s)
Adrenal Gland Neoplasms/radiotherapy , Brachytherapy/mortality , Carcinoma/prevention & control , Carcinoma/secondary , Dose Fractionation, Radiation , Neoplasm Recurrence, Local/mortality , Adrenal Gland Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Carcinoma/mortality , Female , Germany/epidemiology , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/prevention & control , Prevalence , Radiotherapy Dosage , Radiotherapy, Image-Guided , Risk Factors , Survival Rate , Treatment Outcome
3.
Klin Padiatr ; 227(4): 199-205, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26038964

ABSTRACT

BACKGROUND: The German study group for quality assurance in pediatric endocrinology and the University of Ulm have established a software ("Hypo Dok") for the documentation of longitudinal data of patients with congenital primary hypothyroidism (CH). Aim of this study was to analyse the long-term follow-up of patients with CH and to compare treatment with current guidelines. METHODS/PATIENTS: Anonymised data of 1,080 patients from 46 centres were statistically analysed. RESULTS: Newborn screening result was available at a mean age of 7.3 days. Confirmation of the diagnosis was established at 8.4 days and therapy was started at 11 days. The average screening TSH was 180.0 mIU/L. During the first 3 months mean levothyroxine (LT4) dose was 10.7 µg/kg/day or 186.0 µg/m²/day. Weight-, BMI- and height-SDS did not differ significantly from the normal population. Only 25% of the patients (n=262) underwent formal EQ/IQ-testing. Their average IQ was 98.8 ± 13.2 points. DISCUSSION: In Germany screening, confirmation and start of treatment of CH are within the recommended time frame of 14 days. Initial LT4-doses are adequate. The auxological longterm outcome of young CH patients is normal. The implementation of standardized IQ testing has to be improved in routine patient care. CONCLUSION: Longitudinal data of patients with CH was analysed and compared to current guidelines. Confirmation and start of treatment are according to the recommendations. However standardised IQ testing requires improvement.


Subject(s)
Congenital Hypothyroidism/drug therapy , Long-Term Care , Registries , Software , Thyroxine/therapeutic use , Congenital Hypothyroidism/diagnosis , Female , Germany , Guideline Adherence , Humans , Infant , Infant, Newborn , Intelligence/drug effects , Longitudinal Studies , Male , Neonatal Screening , Quality Assurance, Health Care , Treatment Outcome
4.
Anal Bioanal Chem ; 407(17): 5227-33, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25963649

ABSTRACT

Smith-Lemli-Opitz syndrome (SLOS) is an inherited metabolic disease in the cholesterol biosynthesis pathway which is characterised by accumulation of 7- and 8-dehydrocholesterol and by reduced cholesterol concentrations in all tissues and body fluids. With this study, we developed a new, rapid, robust and high-throughput tandem mass spectrometric method as routine application for the selective SLOS screening and therapy monitoring in serum and dried blood. After protein precipitation of 10 µL serum or 4.7 mm dried blood spot, the sum of 7- and 8-dehydrocholesterol (DHC) was analysed by rapid chromatography combined with tandem mass spectrometry. Method comparison with GC-MS was performed for 46 serum samples. A comparison between serum and corresponding dried blood spots for DHC and cholesterol was performed with 40 samples from SLOS patients. Concentrations of DHC and cholesterol were analysed in 2 dried blood samples from newborns with SLOS and 100 unaffected newborns. Intra- and inter-assay variabilities ranged between 3.7 and 17.7% for serum and dried blood spots. Significant correlations between the new LC-MS/MS method and GC-MS were determined for DHC (r = 0.937, p < 0.001) and for cholesterol (r = 0.946, p < 0.001). Significant coefficients of correlation between serum and dried blood spot samples above 0.8 were calculated for both analytes. A cut-off value of 5.95 for the ratio of DHC/cholesterol (multiplied by 1000) was found to distinguish newborns diagnosed with SLOS from normal newborns in a retrospective analysis after 5 years. The developed method enables a rapid quantification of the sum parameter 7- and 8-DHC in newborns and SLOS patients under therapy in serum as well as dried blood spot samples.


Subject(s)
Cholestadienols/blood , Cholesterol/blood , Dehydrocholesterols/blood , Dried Blood Spot Testing/methods , Smith-Lemli-Opitz Syndrome/blood , Tandem Mass Spectrometry/methods , Chromatography, Liquid/economics , Chromatography, Liquid/methods , Dried Blood Spot Testing/economics , Gas Chromatography-Mass Spectrometry/economics , Gas Chromatography-Mass Spectrometry/methods , Humans , Infant, Newborn , Limit of Detection , Tandem Mass Spectrometry/economics
5.
Chirurg ; 86(2): 132-8, 2015 Feb.
Article in German | MEDLINE | ID: mdl-25673224

ABSTRACT

The surgical treatment of primary and secondary liver pathologies is nowadays standard practice. Since the first major resections performed by Langenbruch in 1888 there have been significant developments in the surgical technique. In addition to the surgical technique, the diagnostics and patient selection, perioperative care and anesthetic management as well as knowledge of liver anatomy and physiology have also shown significant developments. The proportion of complex operations, even within the framework of multimodal concepts has also increased. Despite this increasing complexity, the morbidity (< 45 %) and mortality (< 5 %) of liver surgery could be clearly reduced; however, the incidence of postoperative biliary leaks in large published series currently lies between 0 % and 30 % and has only shown a minimal reduction in recent years. The management of bile leakage requires an interdisciplinary management involving endoscopic and radiological, interventional or operative therapy. Most leakages (69-94 %) persist under conservative treatment (drainage and if necessary antibiotic therapy). For high volume fistulas and persistent biliary leakage endoscopic retrograde cholangiography (ERC) with stent placement represents the therapy of choice. Infections with biliary peritonitis and failure of interventional strategies often require revision surgery, possibly consisting of suturing if a leakage is identifiable, replacement of drainages or application of a bile duct drainage (e.g. T-drain or transhepatic external biliary drainage).


Subject(s)
Biliary Fistula/therapy , Hepatectomy , Liver Diseases/surgery , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Postoperative Complications/therapy , Biliary Fistula/etiology , Biliary Fistula/prevention & control , Cholangiopancreatography, Endoscopic Retrograde , Cooperative Behavior , Humans , Interdisciplinary Communication , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Reoperation , Stents
7.
HNO ; 62(3): 165-70, 2014 Mar.
Article in German | MEDLINE | ID: mdl-24610085

ABSTRACT

BACKGROUND: Since 2009, all newborns in Germany have been entitled to universal neonatal hearing screening (UNHS). UNHS with tracking of test results leads to earlier detection of hearing disorders. The Association of German Hearing Screening Centers (Verband Deutscher Hörscreening-Zentralen, VDHZ) was founded to promote nationwide tracking, validity and quality control of UNHS results. OBJECTIVES: A comparable data structure in the different screening centers, with uniform definitions of primary parameters is essential for the nationwide evaluation of UNHS results. To address the question of whether a data structure with comparable definitions already exists or still has to be created, the existing structures and primary parameter definitions in the hearing screening centers should be investigated and compared. METHODS: A survey was conducted in all hearing screening centers to assess how data on the primary UNHS parameters defined in pediatric guidelines was gathered. In the case of discrepancies, uniform definitions were created. Finally, the practicability of these definitions was evaluated. RESULTS: Due to differing definitions of primary parameters, some of the data were not comparable between the individual centers. Therefore, uniform definitions were created in a consensus process. In the centers, the screening method, the two-step first screening and the result of the first screening now correspond to these uniform definitions. Other parameters, e.g. the total number of newborns, still vary widely, rendering the comparison of screening rates almost impossible. CONCLUSION: Valid evaluation of UNHS not only requires nationwide establishment of hearing screening centers, but also unified data structures and parameter definitions.


Subject(s)
Hearing Disorders/classification , Hearing Disorders/diagnosis , Hearing Tests/standards , Mass Screening/standards , Neonatal Screening/standards , Practice Guidelines as Topic , Terminology as Topic , Audiology/standards , Female , Germany , Humans , Infant, Newborn , Male , Otolaryngology/standards
8.
Mol Imaging Biol ; 16(2): 189-98, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24065199

ABSTRACT

PURPOSE: This study was conducted to investigate the capacity of (99m)Tc-labeled 1-thio-ß-D-glucose ((99m)Tc-1-TG) and 5-thio-D-glucose ((99m)Tc-5-TG) to act as a marker for glucose metabolism in tumor cells in vitro. PROCEDURES: We investigated the cellular uptake of (99m)Tc-1-TG, (99m)Tc-5-TG, and 2-deoxy-2-[(18)F]fluoro-D-glucose((18)F-FDG) in a human colorectal carcinoma and human lung adenocarcinoma cell line (HCT-116, A549) at different time points and varying glucose/insulin concentrations and under transporter blockage by cytochalasin-B and phloretin. Cell compartment analysis was performed. RESULTS: A significant uptake and time dependency thereof, a significant uptake dependency on glucose and insulin and a significant uptake inhibition by cytochalasin-B for (99m)Tc-1-TG and (99m)Tc-5-TG, was shown. Albeit substantial, the uptake was less pronounced in (99m)Tc-1-TG and (99m)Tc-5-TG compared with (18)F-FDG. (99m)Tc-1-TG and (99m)Tc-5-TG showed a higher accumulation in the cell membranes compared with (18)F-FDG. CONCLUSION: Tc-1-TG and (99m)Tc-5-TG showed an uptake in vitro with glucose analog characteristics but with membranous accumulation. Tumor imaging should be investigated in an animal model.


Subject(s)
Cell Compartmentation , Fluorodeoxyglucose F18/pharmacokinetics , Glucose/analogs & derivatives , Radiopharmaceuticals/pharmacokinetics , Technetium/pharmacokinetics , Cell Compartmentation/drug effects , Cell Line, Tumor , Cytochalasin B/pharmacology , Glucose/pharmacokinetics , Humans , Insulin/metabolism , Phloretin/pharmacology , Time Factors
9.
Ultraschall Med ; 32(1): 74-80, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21305438

ABSTRACT

Congenital hyperinsulinism (CHI), syn. nesidioblastosis, is the most frequent cause of persistent, recurrent hypoglycemia in infancy. One third of patients show a single circumscribed focus. Enucleation of the focus and the removal of all affected ß-cells with preservation of healthy tissue is the treatment of choice. The intrapancreatic choledochus as well as the ductus pancreaticus major must remain intact. The diagnostic gold standard is 18F-DOPA-PET/CT. Intraoperative sonography is carried out to correctly visualize the focus preoperatively localized by PET/CT in situ during the operation. The enucleation of the focus was carried out 3 - 20 days after PET/CT in 5 patients at an age of 3.5 - 14 months. Intraoperative ultrasound was carried out with high-capacity devices of different manufacturers under use of broadband probes (9 - 14 MHz). The localization by intraoperative ultrasound was accurate in all 5 patients with focal CHI, with regard to the intraoperative localization as previously described by PET/CT and histology. D. choledochus and D. pancreaticus major were separated intraoperatively by ultrasound. 3 of 5 patients were cured by complete enucleation of the focus. Nevertheless, the entire intraoperative identification of the segmented focus is still problematic. Characteristic sonographic features of a CHI focus are: hypoechogenicity, variable homogeneous and inhomogenous texture, blurred, irregular limitation without capsule, filiform, lobular processes, and insular dispersal into the surrounding tissue. Intraoperative high-resolution sonography helps the pediatric surgeon to determine size, configuration and topography of a CHI focus.


Subject(s)
Image Processing, Computer-Assisted/methods , Nesidioblastosis/diagnostic imaging , Nesidioblastosis/surgery , Pancreas/diagnostic imaging , Pancreas/surgery , Ultrasonography/methods , Common Bile Duct/diagnostic imaging , Common Bile Duct/surgery , Equipment Design , Female , Humans , Image Processing, Computer-Assisted/instrumentation , Imaging, Three-Dimensional , Infant , Insulin-Secreting Cells/diagnostic imaging , Intraoperative Period , Male , Pancreatic Ducts/diagnostic imaging , Pancreatic Ducts/surgery , Positron-Emission Tomography , Sensitivity and Specificity , Tomography, X-Ray Computed , Ultrasonography/instrumentation
11.
Horm Res ; 70(2): 65-72, 2008.
Article in English | MEDLINE | ID: mdl-18547951

ABSTRACT

In recent years, considerable progress has been made in the biochemical, morphological and molecular genetic differentiation of congenital hyperinsulinism (CHI). Fluorine-18 L-3,4-dihydroxyphenylalanine positron emission tomography ((18)F-DOPA-PET) has been introduced for differentiation between focal and diffuse CHI. The ability to take up L-DOPA and convert it into dopamine is correlated with the activity of the aromatic amino acid decarboxylase and increased in the hyperfunctional affected pancreatic area in comparison to normally functioning pancreas. The high sensitivity of this method allows the surgeon to perform a curative limited resection of a focus without the risk of long-term diabetes. The exact preoperative planning by (18)F-DOPA-PET/CT computer tomography allows laparoscopic operation in selected cases with the focus in the tail and limits necessity to open the pancreatic duct in cases with focus in the head. Patients with persistent CHI should be managed within a strong network of diagnostic, treatment, and research institutions.


Subject(s)
Congenital Hyperinsulinism/diagnosis , Dihydroxyphenylalanine , Fluorine Radioisotopes , Positron-Emission Tomography , Algorithms , Congenital Hyperinsulinism/surgery , Humans , Pancreas/surgery , Preoperative Care
12.
Horm Res ; 70(1): 59-64, 2008.
Article in English | MEDLINE | ID: mdl-18493152

ABSTRACT

BACKGROUND: Congenital hyperinsulinism (CHI) is characterized by severe hypoglycemia caused by dysregulated insulin secretion. The long-term outcome is dependent on prevention of hypoglycemic episodes to avoid the high risk of permanent brain damage. Severe cases are usually resistant to diazoxide or nifedipine. In addition, somatostatin analogues are ineffective in a subgroup of patients to achieve stable euglycemia. In these infants the only remaining long-term option has been subtotal pancreatectomy with high risk of diabetes mellitus. Intravenous infusions of glucagon are used as immediate treatment to stabilize euglycemia in affected newborns. The rationale of this treatment comes from the observation of an increased glycogen content of the liver when glycogenolysis is inhibited by insulin. OBJECTIVE: To review the efficacy and safety of long-term subcutaneous glucagon infusion as a potential therapeutic option for blood glucose stabilization in infants with severe CHI without the need of additional intravenous glucose or immediate surgical intervention. METHOD: Retrospective review of 9 children with CHI who received continuous subcutaneous infusion of glucagon for weeks or months. Glucagon was added to octreotide to replace octreotide-induced suppression of endogenous glucagon secretion, thereby liberating glucose by stimulation of hepatic glycogenolysis. In 3 cases, a stabilized formulation of glucagon was used to prevent glucagon crystallization that frequently occurs in smaller volumes. RESULTS: Introduction of glucagon allowed the reduction or discontinuation of central glucose infusion in all children studied. In 2 patients, glucagon was introduced due to recurrent hypoglycemia despite subtotal pancreatectomy. Six out of 9 children were discharged home on this treatment, which their parents were able to continue without further symptomatic hypoglycemia, convulsions or unconsciousness. In 3 children, subcutaneous glucagon was continuously administered for 1-4 years leading to stable euglycemia. However, 2 children with diffuse type still required subtotal pancreatectomy. As a possible side effect, 2 children developed erythema necrolyticum, which resolved after discontinuation of the glucagon infusion. This has been described before in glucagonoma. CONCLUSION: In this retrospective series, combination therapy of low-dose octreotide and subcutaneous glucagon infusion has been effective in preventing hypoglycemic episodes in severe CHI. We propose this may serve as a therapeutic option in place of high rates of glucose infusion through a central venous catheter and as an alternative to subtotal pancreatectomy in diffuse type of CHI.


Subject(s)
Congenital Hyperinsulinism/drug therapy , Gastrointestinal Agents/administration & dosage , Glucagon/administration & dosage , Octreotide/administration & dosage , Blood Glucose/analysis , Brain Diseases, Metabolic/blood , Brain Diseases, Metabolic/prevention & control , Congenital Hyperinsulinism/blood , Congenital Hyperinsulinism/complications , Female , Gastrointestinal Agents/adverse effects , Glucagon/adverse effects , Glycogen/metabolism , Humans , Hypoglycemia/blood , Hypoglycemia/prevention & control , Infant, Newborn , Male , Octreotide/adverse effects , Pancreatectomy , Retrospective Studies
14.
Neuropediatrics ; 38(2): 88-90, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17712737

ABSTRACT

Marinesco-Sjögren syndrome (MSS) is an autosomal recessive multiorgan disorder with clinical and genetic heterogeneity. The key features of MSS include cerebellar ataxia, early bilateral cataracts, delayed motor development, and to a varying degree mental retardation. The syndrome was recently mapped to chromosome 5q31, and loss-of-function mutations in the SIL1 gene have been identified as the primary pathology. Here, we describe two German siblings with clinical characteristics resembling those seen in many cases of MSS except that a marked cerebellar atrophy was not detectable in our patients. In addition, both patients presented with external ophthalmoplegia and paralytic dysphagia. Sequencing of all 10 exons of the SIL1 gene did not detect any SIL1 mutation in our patients.


Subject(s)
Cataract/congenital , Cataract/pathology , Cerebellar Ataxia/pathology , Deglutition Disorders/pathology , Ophthalmoplegia/pathology , Adult , Cataract/genetics , Cerebellar Ataxia/genetics , Child , Deglutition Disorders/genetics , Female , Guanine Nucleotide Exchange Factors/genetics , Humans , Infant , Male , Ophthalmoplegia/genetics , Spinocerebellar Degenerations/genetics , Spinocerebellar Degenerations/pathology , Syndrome
15.
Cytogenet Genome Res ; 116(1-2): 146-51, 2007.
Article in English | MEDLINE | ID: mdl-17268195

ABSTRACT

In a four-week-old child with female external and internal genitalia but with clitoris hypertrophy chromosome analysis from blood lymphocytes revealed a 46,XY karyotype. No deletion of Y chromosomal sequences was detected by PCR analysis of genomic DNA isolated from peripheral blood leucocytes. Because of the increased risk for gonadal tumours, gonadectomy was performed. Conventional cytogenetic analysis of the left dysgenetic gonad revealed a gonosomal mosaicism with a 45,X cell line in 27 of 50 metaphases. The dysgenetic left gonad demonstrated a significantly higher proportion (P = 0.005) of cells carrying a Y chromosome (46.3%) than the streak gonad from the right side (33.9%). Histomorphological examination of the left gonad revealed immature testicular tissue and rete-like structures as well as irregular ovarian type areas with cystic follicular structures. Interphase FISH analysis of the different tissues of this dysgenetic gonad demonstrated variable proportions of cells with an X and a Y chromosome. Whereas Sertoli cells and rete-like structures revealed a significantly higher proportion of XY cells in relation to the whole section of the dysgenetic gonad (P < 0.0001), almost all granulose-like cells carried no Y chromosome. The proportion of XY/X cells in theca-like cells and Leydig cells was similar to that of the whole dysgenetic gonad. In contrast to these findings, spermatogonia exclusively contained an XY constellation.


Subject(s)
Gonadal Dysgenesis/genetics , Gonads/anatomy & histology , Immunohistochemistry/methods , In Situ Hybridization, Fluorescence/methods , Sex Chromosome Aberrations , Sex Chromosomes/ultrastructure , Chromosomes, Human, X/genetics , Chromosomes, Human, Y/genetics , Female , Gonads/pathology , Humans , Infant, Newborn , Karyotyping , Sex Determination Processes
17.
Dtsch Med Wochenschr ; 131(15): 821-4, 2006 Apr 13.
Article in German | MEDLINE | ID: mdl-16607603

ABSTRACT

In patients with craniopharyngioma, pituitary failure and often lifelong hormone replacement therapy, persisting ophthalmological problems with impaired vision, cranial nerve palsies, and psychoneurological deficits will lead to a persisting impairment in quality of life and social competence. Some patients completely depend on assistance. To prevent this, a major goal is an early diagnosis and limitation of operative radicality to minimize postoperative complications. Surgery in centers with special expertise is mandatory. Radiotherapeutical strategies are relatively safe and improve the outcome and recurrence-free survival after incomplete surgical resection or after local recurrence. Multidisciplinary concepts and prospective data acquisition are desirable with regard to therapy and outcome in patients with craniopharyngioma. Problems in the follow-up period are the development of atherosclerotic complications and metabolic syndrome as a consequence of occasionally excessive obesity, which may impair the long-term survival of the patients. Cause and progression of these complications are not fully understood, therapeutical strategies for the morbid obesity are not available. Only interdisciplinary co-operation will help to develop and evaluate therapeutical concepts for the management of this rare disease.


Subject(s)
Craniopharyngioma/diagnosis , Hypothalamic Diseases/etiology , Pituitary Neoplasms/diagnosis , Combined Modality Therapy , Continuity of Patient Care , Craniopharyngioma/complications , Craniopharyngioma/therapy , Humans , Hypothalamic Diseases/drug therapy , Pituitary Neoplasms/complications , Pituitary Neoplasms/therapy , Prognosis , Treatment Outcome
18.
Mol Pathol ; 55(1): 40-5, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11836446

ABSTRACT

BACKGROUND: Alterations in the insulin-like growth factor (IGF) system have been reported for different tumours. They are of particular interest in the search for new prognostic and therapeutic approaches in cancer. In childhood acute lymphoblastic leukaemia (ALL) the amount of "tumour mass" at diagnosis can exceed 1 kg. To understand the endocrine, paracrine, and autocrine potential of the malignant transformed progenitor cells, the ability of these cells to express components of the IGF system needs to be investigated. AIM: To characterise the expression pattern of genes of the IGF system in malignant lymphoblasts of children suffering from ALL. METHODS: Reverse transcription polymerase chain reaction of Ficoll separated mononuclear cells from 142 children with ALL, 127 cord blood samples, and 55 blood samples of age matched controls were studied. RESULTS: The expression of IGF-I, IGF-II, IGF binding protein 5 (IGFBP-5), and CTGF (IGFBP-rP2) was seen in a higher proportion of mononuclear cells of patients with ALL than in controls. Patients with ALL who were in continuous remission had a lower percentage of IGFBP-2 and IGFBP-3 expressing mononuclear cells at diagnosis than did those who developed a relapse. Only malignant lymphoblasts of B cell origin showed expression of CTGF (IGFBP-rP2). Malignant lymphoblasts of T cell origin more often expressed IGFBP-2 and IGFBP-5, whereas IGF-II and IGFBP-3 expression was seen more often in lymphoblasts of B cell origin. CONCLUSIONS: Malignant lymphoblasts of patients with ALL express components of the IGF system and therefore promote their own growth in an autocrine, paracrine, or endocrine manner. Whether these components will be useful as prognostic factors in the stratification of ALL treatment in children needs to be evaluated.


Subject(s)
Biomarkers, Tumor/metabolism , Neoplasm Proteins/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Somatomedins/metabolism , Biomarkers, Tumor/genetics , Child , Gene Expression , Humans , Infant, Newborn , Insulin-Like Growth Factor Binding Proteins/genetics , Insulin-Like Growth Factor Binding Proteins/metabolism , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor II/genetics , Insulin-Like Growth Factor II/metabolism , Logistic Models , Neoplasm Proteins/genetics , Prospective Studies , Signal Transduction , Somatomedins/genetics
19.
Eur J Pediatr ; 160(9): 561-5, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11585080

ABSTRACT

UNLABELLED: The short stature homeobox-containing gene (SHOX) on the short arm of the X and Y chromosomes is an important determining factor of stature phenotype. Absence of the SHOX gene is a main cause for short stature in patients with Turner syndrome. Mutations of the SHOX gene can also be responsible for Léri-Weill syndrome (dyschondrosteosis). The aim of this study was to determine the frequency of SHOX deletions in short stature children and to delineate indications for SHOX deletion screening. Out of 50 probands, 35 had idiopathic short stature, 12 cases showed additional anomalies of the forearms (in particular Madelung deformity) and three patients were affected by a congenital heart defect. Chromosomal investigations with fluoresence in situ hybridisation did not reveal a SHOX deletion in any patient with idiopathic short stature. In five of the 12 patients (41.7%) with anomalies of the forearms, a SHOX deletion on one sex chromosome could be detected. No deletion was observed in the three cases with additional heart defects. CONCLUSION: The frequency of short stature homeobox-containing gene deletions in patients with idiopathic short stature appears to be very low and does not require a fluorescence in situ hybridisation analysis. Short stature in association with anomalies of the forearms such as Madelung deformity makes a deletion more probable and therefore screening for such deletions is recommended in these cases.


Subject(s)
Body Height/genetics , Gene Deletion , Genes, Homeobox , Homeodomain Proteins/genetics , Adolescent , Child , Child, Preschool , Female , Genetic Testing , Germany , Humans , In Situ Hybridization, Fluorescence , Infant, Newborn , Male , Phenotype , Short Stature Homeobox Protein
20.
Hum Hered ; 52(3): 177-82, 2001.
Article in English | MEDLINE | ID: mdl-11588402

ABSTRACT

We report on an 18-year-old female with de novo tandem duplication Xq23-->Xq27-28. The breakpoints of the duplication segment have been mapped by FISH using a panel of locus specific YACs. Despite selective inactivation of the aberrant X chromosome, proven by a combination of molecular and cytogenetic studies, the patient exhibits mental retardation, dysmorphic features and short stature. Possible mechanisms explaining this unexpected finding are discussed.


Subject(s)
Intellectual Disability/genetics , X Chromosome , Adolescent , Chromosome Aberrations , Chromosome Banding , Chromosome Mapping , Female , Humans , In Situ Hybridization, Fluorescence , Phenotype
SELECTION OF CITATIONS
SEARCH DETAIL
...